Dabigatran dose testing needed: BMJ

All patients starting dabigatran should undergo initial drug-level monitoring and dose adjustment due to a wide variation in plasma levels of the drug, a BMJ analysis suggests.

An in-depth investigation by the journal published Thursday reports on new evidence of a fivefold variation in dabigatran (Pradaxa) levels that it says may put some patients with atrial fibrillation at risk of serious bleeding, and leave others undertreated for stroke risk.

The journal

Latest

Trending